Top Reasons CAR T-Cell Therapies Not Offered by HCPs in Japan^1,a,b

In Japan, practice capability and limited capacity for administration, as well as the need for referral, were top reasons for not offering CAR T-cell therapy to patients

^aTop reason defined as any reason that was given by more than 25% of HCPs during the survey. ^bQuestions about BsAb therapy were not asked to HCPs in Japan.

BsAb, bispecific antibody; CAR, chimeric antigen receptor; HCP, health care professional.

Reference

Zamagni E, Kevin B, Cormier N, et al. Differences across countries in healthcare provider confidence with CAR-T and bispecific antibody therapies for relapsed/refractory multiple myeloma. Presented at: EHA 2025 Congress; June 12-15, 2025; Milan, Italy. Poster PS1751.

Top Reasons CAR T-Cell Therapies Not Offered by HCPs in Japan1,a,b

In Japan, practice capability and limited capacity for administration, as well as the need for referral, were top reasons for not offering CAR T-cell therapy to patients

Reference

Top Reasons CAR T-Cell Therapies Not Offered by HCPs in Japan^1,a,b